These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26973069)

  • 1. Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated Vibrio cholerae.
    Lebens M; Terrinoni M; Karlsson SL; Larena M; Gustafsson-Hedberg T; Källgård S; Nygren E; Holmgren J
    Vaccine; 2016 Apr; 34(18):2121-8. PubMed ID: 26973069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
    Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
    Kundu J; Mazumder R; Srivastava R; Srivastava BS
    FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTA1: Purified and display onto gram-positive enhancer matrix (GEM) particles as mucosal adjuvant.
    Zhang Y; Yu X; Hou L; Chen J; Li P; Qiao X; Zheng Q; Hou J
    Protein Expr Purif; 2018 Jan; 141():19-24. PubMed ID: 28866467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery.
    Davoodi-Semiromi A; Schreiber M; Nalapalli S; Verma D; Singh ND; Banks RK; Chakrabarti D; Daniell H
    Plant Biotechnol J; 2010 Feb; 8(2):223-42. PubMed ID: 20051036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical immunogenicity and protective efficacy of an oral Helicobacter pylori inactivated whole cell vaccine and multiple mutant cholera toxin: A novel and non-toxic mucosal adjuvant.
    Holmgren J; Nordqvist S; Blomquist M; Jeverstam F; Lebens M; Raghavan S
    Vaccine; 2018 Oct; 36(41):6223-6230. PubMed ID: 30119923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
    Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
    Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
    Tamura SI; Kurata T
    Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rice-based oral cholera vaccine induces macaque-specific systemic neutralizing antibodies but does not influence pre-existing intestinal immunity.
    Nochi T; Yuki Y; Katakai Y; Shibata H; Tokuhara D; Mejima M; Kurokawa S; Takahashi Y; Nakanishi U; Ono F; Mimuro H; Sasakawa C; Takaiwa F; Terao K; Kiyono H
    J Immunol; 2009 Nov; 183(10):6538-44. PubMed ID: 19880451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and characterization of an auxotrophic ctxA mutant of O139 Vibrio cholerae.
    Chan M; Cheong TG; Kurunathan S; Chandrika M; Ledon T; Fando R; Lalitha P; Zainuddin ZF; Ravichandran M
    Microb Pathog; 2010 Nov; 49(5):211-6. PubMed ID: 20558271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neonatal sublingual vaccination with Salmonella proteins and adjuvant cholera toxin or CpG oligodeoxynucleotides induces mucosal and systemic immunity in mice.
    Huang CF; Wang CC; Wu TC; Wu KG; Lee CC; Peng HJ
    J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):262-71. PubMed ID: 18376242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fusion-expressed CtxB-TcpA-C-CPE improves both systemic and mucosal humoral and T-cell responses against cholera in mice.
    Souod N; Kargar M; Hoseini MH; Jafarinia M
    Microb Pathog; 2021 Aug; 157():104978. PubMed ID: 34022352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.
    Pizza M; Giuliani MM; Fontana MR; Monaci E; Douce G; Dougan G; Mills KH; Rappuoli R; Del Giudice G
    Vaccine; 2001 Mar; 19(17-19):2534-41. PubMed ID: 11257389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine.
    Hagiwara Y; Komase K; Chen Z; Matsuo K; Suzuki Y; Aizawa C; Kurata T; Tamura S
    Vaccine; 1999 Jul; 17(22):2918-26. PubMed ID: 10438064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens.
    Lycke N; Holmgren J
    Immunology; 1986 Oct; 59(2):301-8. PubMed ID: 3021614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infection and immunity to Vibrio cholerae, Salmonella typhimurium and Escherichia coli in a rabbit model.
    Guinée PA; Jansen WH; Rijpkema SG
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 Nov; 270(1-2):260-9. PubMed ID: 2464884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholera toxin-B (ctxB) antigen expressing Salmonella Typhimurium polyvalent vaccine exerts protective immune response against Vibrio cholerae infection.
    Vishwakarma V; Sahoo SS; Das S; Ray S; Hardt WD; Suar M
    Vaccine; 2015 Apr; 33(15):1880-9. PubMed ID: 25701672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.